Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study

Mamiko Onuki; Fumiaki Takahashi; Takashi Iwata; Hiroshi Nakazawa; Hideaki Yahata; Hiroyuki Kanao; Koji Horie; Katsuyuki Konnai; Ai Nio; Kazuhiro Takehara; Shoji Kamiura; Naotake Tsuda; Yuji Takei; Shogo Shigeta; Noriomi Matsumura; Hiroyuki Yoshida; Takeshi Motohara; Hiroyuki Yamazaki; Keiichiro Nakamura; Junzo Hamanishi; Nobutaka Tasaka; Mitsuya Ishikawa; Yasuyuki Hirashima; Wataru Kudaka; Mayuyo Mori-Uchino; Iwao Kukimoto; Takuma Fujii; Yoh Watanabe; Kiichiro Noda; Hiroyuki Yoshikawa; Nobuo Yaegashi; Koji Matsumoto

doi:10.1111/cas.15943

Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study

Mamiko Onuki, Fumiaki Takahashi, Takashi Iwata, Hiroshi Nakazawa, Hideaki Yahata, Hiroyuki Kanao, Koji Horie, Katsuyuki Konnai, Ai Nio, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, Yuji Takei, Shogo Shigeta, Noriomi Matsumura, Hiroyuki Yoshida, Takeshi Motohara, Hiroyuki Yamazaki, Keiichiro Nakamura, Junzo HamanishiNobutaka Tasaka, Mitsuya Ishikawa, Yasuyuki Hirashima, Wataru Kudaka, Mayuyo Mori-Uchino, Iwao Kukimoto, Takuma Fujii, Yoh Watanabe, Kiichiro Noda, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto

Obstetrics & Gynecology

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high-grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population-based cancer registry, the incidence of ICC among young women aged 20–29 years showed a significant decline from 3.6 to 2.8 per 100 000 women-years during 2016–2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20–29 years also decreased from 256 cases to 135 cases during 2011–2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20–29 years during 2017–2022 (90.5%–64.7%, p = 0.05; Cochran–Armitage trend test). This is the first report to suggest population-level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.

Original language	English
Pages (from-to)	4426-4432
Number of pages	7
Journal	Cancer science
Volume	114
Issue number	11
DOIs	https://doi.org/10.1111/cas.15943
Publication status	Published - 11-2023

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cas.15943

Cite this

Onuki, M., Takahashi, F., Iwata, T., Nakazawa, H., Yahata, H., Kanao, H., Horie, K., Konnai, K., Nio, A., Takehara, K., Kamiura, S., Tsuda, N., Takei, Y., Shigeta, S., Matsumura, N., Yoshida, H., Motohara, T., Yamazaki, H., Nakamura, K., ... Matsumoto, K. (2023). Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study. Cancer science, 114(11), 4426-4432. https://doi.org/10.1111/cas.15943

@article{ab494f68cb384783af9c63aeea43cf12,

title = "Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study",

abstract = "The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high-grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population-based cancer registry, the incidence of ICC among young women aged 20–29 years showed a significant decline from 3.6 to 2.8 per 100 000 women-years during 2016–2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20–29 years also decreased from 256 cases to 135 cases during 2011–2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20–29 years during 2017–2022 (90.5%–64.7%, p = 0.05; Cochran–Armitage trend test). This is the first report to suggest population-level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.",

author = "Mamiko Onuki and Fumiaki Takahashi and Takashi Iwata and Hiroshi Nakazawa and Hideaki Yahata and Hiroyuki Kanao and Koji Horie and Katsuyuki Konnai and Ai Nio and Kazuhiro Takehara and Shoji Kamiura and Naotake Tsuda and Yuji Takei and Shogo Shigeta and Noriomi Matsumura and Hiroyuki Yoshida and Takeshi Motohara and Hiroyuki Yamazaki and Keiichiro Nakamura and Junzo Hamanishi and Nobutaka Tasaka and Mitsuya Ishikawa and Yasuyuki Hirashima and Wataru Kudaka and Mayuyo Mori-Uchino and Iwao Kukimoto and Takuma Fujii and Yoh Watanabe and Kiichiro Noda and Hiroyuki Yoshikawa and Nobuo Yaegashi and Koji Matsumoto",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",

year = "2023",

month = nov,

doi = "10.1111/cas.15943",

language = "English",

volume = "114",

pages = "4426--4432",

journal = "Cancer science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "11",

}

Onuki, M, Takahashi, F, Iwata, T, Nakazawa, H, Yahata, H, Kanao, H, Horie, K, Konnai, K, Nio, A, Takehara, K, Kamiura, S, Tsuda, N, Takei, Y, Shigeta, S, Matsumura, N, Yoshida, H, Motohara, T, Yamazaki, H, Nakamura, K, Hamanishi, J, Tasaka, N, Ishikawa, M, Hirashima, Y, Kudaka, W, Mori-Uchino, M, Kukimoto, I, Fujii, T, Watanabe, Y, Noda, K, Yoshikawa, H, Yaegashi, N & Matsumoto, K 2023, 'Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study', Cancer science, vol. 114, no. 11, pp. 4426-4432. https://doi.org/10.1111/cas.15943

TY - JOUR

T1 - Human papillomavirus vaccine impact on invasive cervical cancer in Japan

T2 - Preliminary results from cancer statistics and the MINT study

AU - Onuki, Mamiko

AU - Takahashi, Fumiaki

AU - Iwata, Takashi

AU - Nakazawa, Hiroshi

AU - Yahata, Hideaki

AU - Kanao, Hiroyuki

AU - Horie, Koji

AU - Konnai, Katsuyuki

AU - Nio, Ai

AU - Takehara, Kazuhiro

AU - Kamiura, Shoji

AU - Tsuda, Naotake

AU - Takei, Yuji

AU - Shigeta, Shogo

AU - Matsumura, Noriomi

AU - Yoshida, Hiroyuki

AU - Motohara, Takeshi

AU - Yamazaki, Hiroyuki

AU - Nakamura, Keiichiro

AU - Hamanishi, Junzo

AU - Tasaka, Nobutaka

AU - Ishikawa, Mitsuya

AU - Hirashima, Yasuyuki

AU - Kudaka, Wataru

AU - Mori-Uchino, Mayuyo

AU - Kukimoto, Iwao

AU - Fujii, Takuma

AU - Watanabe, Yoh

AU - Noda, Kiichiro

AU - Yoshikawa, Hiroyuki

AU - Yaegashi, Nobuo

AU - Matsumoto, Koji

PY - 2023/11

Y1 - 2023/11

N2 - The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high-grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population-based cancer registry, the incidence of ICC among young women aged 20–29 years showed a significant decline from 3.6 to 2.8 per 100 000 women-years during 2016–2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20–29 years also decreased from 256 cases to 135 cases during 2011–2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20–29 years during 2017–2022 (90.5%–64.7%, p = 0.05; Cochran–Armitage trend test). This is the first report to suggest population-level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.

AB - The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high-grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population-based cancer registry, the incidence of ICC among young women aged 20–29 years showed a significant decline from 3.6 to 2.8 per 100 000 women-years during 2016–2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20–29 years also decreased from 256 cases to 135 cases during 2011–2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20–29 years during 2017–2022 (90.5%–64.7%, p = 0.05; Cochran–Armitage trend test). This is the first report to suggest population-level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85170567117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170567117&partnerID=8YFLogxK

U2 - 10.1111/cas.15943

DO - 10.1111/cas.15943

M3 - Article

C2 - 37688310

AN - SCOPUS:85170567117

SN - 1347-9032

VL - 114

SP - 4426

EP - 4432

JO - Cancer science

JF - Cancer science

IS - 11

ER -

Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this